Interview with Michael Pehl, Managing Director, Celgene Germany
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Address: An der Wiek 7, 17493 Greifswald – Insel Riems,Germany
Tel: +49 38351 76-0
RIEMSER Arzneimittel AG is a company with tradition and a future.Following its demerger from the Friedrich-Loeffler-Institute Riems Island (FLI), RIEMSER Arzneimittel AG has, within a period of just a few years, evolved to become one of East Germany’s largest producers and developers of pharmaceutical products.RIEMSER has affiliated branches in such German Federal States such as Saarland, Baden-Württemberg, and Saxony as well as abroad. The company has more than 618 employees at various locations. In 2008, the group achieved sales of the order of 85,4 million euros. RIEMSER exports to more than 80 countries, including China, Russia and the U.S.A. Business transacted abroad will grow to more than 40 percent of total sales in fiscal 2009. The company prides itself on a well-diversified portfolio, which encompasses the areas human, veterinary, and dental. Its core competencies focus on oncology and dermatology as well as on dental products and anti-infectives, in veterinary, the emphasis is on animal vaccines.
Celgene is very new in the German market. What would you say have been the main achievements of Celgene Germany since its establishment in 2006? Celgene Germany started as a…
Could you briefly present the Association of German Biotechnology Companies (VBU) and DECHEMA e.V. to our readers and describe their importance to the German biotechnology industry? VBU is a non…
Hospira, which was spun-off from Abbott Laboratories in 2004, is a global specialty pharmaceutical and medication delivery company driven by its vision of Advancing Wellness™. Bringing proven leadership and experience,…
How challenging is for you as General Manager of Nycomed Germany to lead the number one subsidiary of the Nycomed Group and what would you highlight as the key milestones…
The acquisition of IVAX in 2006 was decisive to establish Teva as the number one generic producer worldwide and further consolidate the company in the German market; and this process…
See our Cookie Privacy Policy Here